

Contents

Welcome Message	iii
EULAR 2015 Abstracts Reviewers	iv

Speakers Abstracts

Speaker Presentations

Wednesday, 10 June 2015

SP0001–SP0002	Health Professional welcome session	2
SP0003–SP0004	WIN session 1	2
SP0005	Psoriatic arthritis - a clinical perspective	2
SP0006–SP0009	Difficult vasculitis	3
SP0010	HOT session 1	4
SP0011–SP0012	Do new anti-osteoporotic drugs have an additional effect on bone quality?	4
SP0013–SP0014	Optimising the use of electronic information and technology in clinic and research	4
SP0015	Autoinflammatory diseases	5
SP0016–SP0018	Co-stimulation: towards genuine immune modulation	5
SP0019	Estrogens: critical regulator of the immune response; implication for sex bias in the development of autoimmunity	5
SP0020	Training of rheumatology across Europe	6
SP0021–SP0024	Get on the move with rheumatic and musculoskeletal disease	6
SP0025–SP0028	Building sustainable relationships between patients and researchers	7
SP0029	Improving your graphs and tables for publication and presentation	8
SP0030–SP0031	What is the impact of imaging on the management of rheumatoid arthritis?	8
SP0032	Calcinosis	8
SP0033–SP0035	HOT session 2	9
SP0036–SP0037	Pregnancy in rheumatic disease	10
SP0038	Searching for evidence to support clinical practice - using non-steroidals as an example	10
SP0039–SP0041	From children to adults	11
SP0042–SP0044	Computers in rheumatology - friends or foes?	11
SP0045	Food and the immune system	12
SP0046–SP0048	Ethnicity - a blind spot within rheumatology?	12
SP0049–SP0051	Measuring success - how to evaluate the impact of your campaign	13
SP0052–SP0055	Capillaroscopy I	14

Thursday, 11 June 2015

SP0056–SP0058	Beyond GWA: functional genomics	15
SP0059–SP0060	Inflammation and fatigue	16
SP0061	WIN session 2	17
SP0062–SP0063	HOT session 3	17
SP0064–SP0066	Championing work	17
SP0067	WIN session 3	18
SP0068–SP0069	Perspectives on stratified medicine in RA	18
SP0070–SP0072	Glucocorticoid sparing in non-RA rheumatic diseases	19
SP0073	HOT session 4	19
SP0074–SP0075	Use and abuse of opioids in non-malignant pain	20
SP0076–SP0078	Functioning measures of function: PROM's and CROM's in the light of the WHO ICF	20
SP0079–SP0081	Dermatomyositis 1	21
SP0082–SP0083	New players in lupus	21
SP0084–SP0085	A painful joint - where is the pain coming from?	22
SP0086–SP0090	International experience	22

SP0091–SP0093	Cardiovascular risk assessment - getting to grips with the challenges	23
SP0094–SP0096	Lost in the system - how to use innovative care to bring health services back to the patient	24
SP0097–SP0098	WIN session 4	25
SP0099–SP0100	Axial SpA: disease modification	25
SP0101–SP0104	Clinically suspect arthralgia	26
SP0105–SP0106	HOT session 5	26
SP0107–SP0108	Regenerative rheumatology	27
SP0109–SP0110	Work productivity as an outcome measure	28
SP0111–SP0112	Dermatomyositis II	28
SP0113–SP0114	The shared mechanisms of arthritis and atherosclerosis	28
SP0115	Imaging & structure of the immune system	29
SP0116	Being a researcher in the rheumatology world	29
SP0117–SP0118	Innovations in healthcare - can you Google it?	29
SP0119–SP0121	Who cares? Primary care focus	30
SP0122–SP0124	Ultrasound advanced I	30
SP0125–SP0126	ABC of biopsies: when to perform and how to interpret I	31
Friday, 12 June 2015		
SP0127–SP0128	Transition from chronic inflammation to cancer: the basic story	31
SP0129–SP0130	Complement as a driver and target in inflammatory disease	32
SP0131–SP0132	WIN session 5	33
SP0133–SP0134	HOT session 6	33
SP0135–SP0136	WIN session 6	33
SP0137–SP0138	Therapeutic insights from early clinical studies in SLE	34
SP0139–SP0141	Autoinflammatory disease	34
SP0142	HOT session 7	35
SP0143	Are we ready for RCTs in scleroderma? Importance of disease stratification and application of predictive markers	35
SP0144–SP0145	Predicting the development of RA	36
SP0146	Other myopathies	36
SP0147–SP0148	New insights in osteo-immunology	36
SP0149–SP0150	New pathogenic aspects in vasculitis	37
SP0151–SP0152	Evidence based medicine. To design and understand clinical trials and meta-analysis	37
SP0153–SP0156	Social and work participation - research into practice	37
SP0157–SP0159	What is new? Latest advances in treatment and management	38
SP0160–SP0162	Capillaroscopy II	39
SP0163	Improving your graphs and tables for publication and presentation	40
SP0164–SP0165	WIN session 7	40
SP0166–SP0167	Combination therapy with biologics in rheumatic diseases - what does the future hold?	41
SP0168–SP0170	Polymyalgia rheumatica versus elderly onset rheumatoid arthritis: a diagnostic challenge	41
SP0171–SP0172	HOT session 8	42
SP0173–SP0175	Treatment and outcome measures in inflammatory myopathies. Update on pharmacological and physical therapy and how to assess	42
SP0176	From basic science: JIA pathogenesis	43
SP0177–SP0179	Scleroderma mechanisms - new perspectives	43
SP0180–SP0181	EULAR/EFIS session: Autoimmunity and inflammation in anti-checkpoint antibody therapies of cancer?	44
SP0182–SP0184	The art of writing	44
SP0185–SP0188	Fit to fight rheumatic and musculoskeletal diseases - how much exercise is beneficial and safe?	45
SP0189	Patient reported outcomes and the EULAR outcome measure toolkit	45
SP0190–SP0192	Youth in action	46
SP0193	MRI I	47
Saturday, 13 June 2015		
SP0194–SP0195	WIN session 8	47
SP0196–SP0197	Comorbidities	47
SP0198	Diagnosis of back pain - suspicion of SpA	48
SP0199	HOT session 9	48
SP0200–SP0202	Coagulation and rheumatology	48

SP0203–SP0204	New challenges in clinical trials	49
SP0205–SP0207	Juvenile localized scleroderma	49
SP0208–SP0210	Autoimmune B-cells in human disease	50
SP0211–SP0213	Bone phenotypes of osteoarthritis: towards personalised treatment	51
SP0214–SP0215	Strategic decisions in a career	52
SP0216–SP0219	Unlocking the mystery of health economics	52
SP0220–SP0222	Family business	53
SP0223	MRI II	54
SP0224–SP0225	WIN session 9	54
SP0226	Viral infections and biologics	55
SP0227–SP0230	Poly-autoimmune diseases	55
SP0231–SP0232	HOT session 10	56
SP0233–SP0234	Treatment and prognosis for OA beyond the knee	56
SP0235–SP0238	Quality indicators - a way to measure the quality of care	57
SP0239	Systemic sclerosis	58
SP0240–SP0242	Microvesicles and intracellular transport	58
SP0243–SP0244	Why psoriasis in arthritis	59
SP0245–SP0247	The art of teaching rheumatology	59
SP0248–SP0251	Breaking down barriers - implementing non pharmacological guidelines in clinical practice	59
SP0252–SP0254	Taking control: success through empowerment and self-management	61

Scientific Abstracts

Oral Presentations

Wednesday, 10 June 2015

OP0001–OP0002	Psoriatic arthritis - a clinical perspective	64
OP0003–OP0004	Do new anti-osteoporotic drugs have an additional effect on bone quality?	65
OP0005–OP0006	Optimising the use of electronic information and technology in clinic and research	65
OP0007–OP0008	Autoinflammatory diseases	66
OP0009–OP0010	Co-stimulation: towards genuine immune modulation	67
OP0011–OP0012	Training of rheumatology across Europe	68
OP0013	Get on the move with rheumatic and musculoskeletal disease	69
OP0014-PARE	Building sustainable relationships between patients and researchers	69
OP0015–OP0016	What is the impact of imaging on the management of rheumatoid arthritis?	69
OP0017–OP0018	Pregnancy in rheumatic disease	70
OP0019–OP0020	Searching for evidence to support clinical practice - using non-steroidals as an example .	71
OP0021–OP0022	From children to adults	72
OP0023	Food and the immune system	73
OP0024-HPR	Ethnicity - a blind spot within rheumatology?	73
OP0025-PARE–OP0026-PARE	Measuring success - how to evaluate the impact of your campaign	74

Thursday, 11 June 2015

OP0027–OP0028	Beyond GWA: functional genomics	75
OP0029–LB0001	Abstract session: Developments in the treatment of RA	75
OP0037–OP0045	Abstract session: SpA clinical	80
OP0046–OP0053	Abstract session: Epidemiology and health services research	83
OP0054–OP0061	Abstract session: SSc clinical and treatment	87
OP0062–OP0069	PreS Abstract session: Clinical aspects of paediatric rheumatology	91
OP0070–OP0077	Abstract session: The biology of RA	94
OP0078–OP0085	Abstract session: SLE, Sjögren's, APS: etiology, pathogenesis, animal models	98
OP0086–OP0093	Abstract session: SLE, Sjögren's and APS: clinical aspects other than treatment	101
OP0094-HPR–OP0102-HPR	HPR Abstract session: Evidence based practice	104
OP0103–OP0110	Abstract session: Osteoarthritis clinical aspects	107
OP0111-PARE–OP0112-PARE	Championing work	110
OP0113–OP0120	Abstract session: Adaptive immunology in rheumatic disease	111
OP0121–OP0128	Abstract session: Emerging concepts in genomics and genetics	114
OP0129–OP0130	Perspectives on stratified medicine in RA	117

OP0131	Use and abuse of opioids in non-malignant pain	117
OP0132–OP0133	Functioning measures of function: PROM's and CROM's in the light of the WHO ICF	118
OP0134–OP0135	Dermatomyositis 1	119
OP0136–OP0137	New players in lupus	120
OP0138–OP0139	A painful joint - where is the pain coming from?	121
OP0140-HPR–OP0141-HPR	Cardiovascular risk assessment - getting to grips with the challenges	121
OP0142-PARE–OP0143-PARE	Lost in the system - how to use innovative care to bring health services back to the patient	122
OP0144–OP0145	Axial SpA: disease modification	123
OP0146–OP0147	Regenerative rheumatology	123
OP0148–OP0149	Work productivity as an outcome measure	124
OP0150–OP0151	Dermatomyositis II	125
OP0152–OP0153	The shared mechanisms of arthritis and atherosclerosis	126
OP0154–OP0155	Imaging & structure of the immune system	127
OP0156	Being a researcher in the rheumatology world	128
OP0157-HPR	Innovations in healthcare - can you Google it?	128
OP0158-PARE	Who cares? Primary care focus	128
Friday, 12 June 2015		
OP0159	Complement as a driver and target in inflammatory disease	129
OP0160–OP0167	Abstract session: Comorbidities in RA	129
OP0168–OP0175	Abstract session: SpA and PsA treatment	132
OP0176–OP0183	Abstract session: RA prognosis, predictors, outcome	137
OP0184–OP0191	Abstract session: SLE and Sjögren's: new treatment options	141
OP0192–OP0199	PreS Abstract session: Basic aspects in paediatric rheumatology	144
OP0200–OP0208	Abstract session: SpA and PsA basic and translational research	147
OP0209–OP0216	Abstract session: SSc pathogenesis, etiology and animal models	150
OP0217–LB0002	Abstract session: New insights into imaging	153
OP0224-HPR–OP0231-HPR	HPR Abstract session: Getting to grips with evidence	156
OP0232–OP0239	Abstract session: Vasculitis	159
OP0240-PARE–OP0247-PARE	PARE Abstract session	162
OP0248–OP0255	Abstract session: Cartilage - bone - synovium	165
OP0256–OP0263	Abstract session: Cytokines and inflammatory mediators	168
OP0264–OP0265	Therapeutic insights from early clinical studies in SLE	171
OP0266–OP0267	Are we ready for RCTs in scleroderma? Importance of disease stratification and application of predictive markers	172
OP0268–OP0269	Predicting the development of RA	173
OP0270–OP0271	Other myopathies	174
OP0272	New insights in osteo-immunology	175
OP0273–OP0274	New pathogenic aspects in vasculitis	175
OP0275–OP0276	Evidence based medicine. To design and understand clinical trials and meta-analysis	176
OP0277-HPR	Social and work participation - research into practice	177
OP0278–OP0279	Treatment and outcome measures in inflammatory myopathies. Update on pharmacological and physical therapy and how to assess	177
OP0280–OP0281	Cost effectiveness of biologics in RA (joint with clinical science?)	178
OP0282–OP0283	From basic science: JIA pathogenesis	179
OP0284–OP0285	Scleroderma mechanisms - new perspectives	180
OP0286-HPR	Fit to fight rheumatic and musculoskeletal diseases - how much exercise is beneficial and safe?	180
OP0287-PARE–OP0288-PARE	Youth in action	181
Saturday, 13 June 2015		
OP0289–OP0290	Comorbidities	181
OP0291	New challenges in clinical trials	183
OP0292–OP0293	Juvenile localized scleroderma	183
OP0294–OP0295	Autoimmune B-cells in human disease	184
OP0296–OP0297	Bone phenotypes of osteoarthritis: towards personalised treatment	185
OP0298-HPR	Unlocking the mystery of health economics	185
OP0299-PARE–OP0300-PARE	Family business	186
OP0301–OP0302	Viral infections and biologics	187

OP0303–OP0304	Treatment and prognosis for OA beyond the knee	187
OP0305-HPR	Quality indicators - a way to measure the quality of care	188
OP0306–OP0307	Systemic sclerosis	189
OP0308–OP0309	Microvesicles and intracellular transport	189
OP0310–OP0311	Why psoriasis in arthritis	190
OP0312–OP0313	The art of teaching rheumatology	191
OP0314	Breaking down barriers - implementing non pharmacological guidelines in clinical practice	192
OP0315-PARE	Taking control: success through empowerment and self-management	192

Late Breaking Abstracts

Thursday, 11 June 2015

LB0001	Abstract session: Developments in the treatment of RA	79
--------	---	----

Friday, 12 June 2015

LB0002	Abstract session: New insights into imaging	156
--------	---	-----

Poster Presentations

Thursday, 11 June 2015

Guided Poster Tours

T1: THU0001–THU0008	Genetics, epigenetics and microRNA	193
T2: THU0023–THU0032	Innate immune mechanism in rheumatic diseases	201
T3: THU0037–THU0046	RA - pathogenesis and biology	206
T4: THU0078–THU0087	RA - predictors of complications and outcomes 1	220
T5: THU0117–THU0126	RA - prognosis	236
T6: THU0173–THU0180	RA - small molecules 1	256
T7: THU0236–THU0244	Spondyloarthritis treatment	282
T8: THU0373–THU0380	Lupus nephritis - pathogenesis and animal models	331
T9: THU0386–THU0395	Treatment of SLE and Sjögren's - clinical aspects	336
T10: THU0411–THU0418	PsA - outcomes and treatment 1	345
T11: THU0437–THU0446	Osteoarthritis	358
T12: THU0573–THU0582	Education in rheumatology	407
T13: THU0603-HPR–THU0610-HPR	HPR: Getting to grips with the evidence	1310
T14: PARE0001–PARE0011	PARE 1	1358

Posters

THU0001–THU0022	Genomics, genetics and epigenetics of rheumatic diseases	193
THU0023–THU0036	Innate immunity in rheumatic diseases	201
THU0037–THU0077	Rheumatoid arthritis - etiology, pathogenesis and animal models	206
THU0078–THU0126	Rheumatoid arthritis - prognosis, predictors and outcome	220
THU0127–THU0172	Rheumatoid arthritis - comorbidity and clinical aspects	240
THU0173–THU0191	Rheumatoid arthritis - non biologic treatment and small molecules	256
THU0192–THU0244	Spondyloarthritis - treatment	264
THU0245–THU0262	Infection-related rheumatic diseases	286
THU0263–THU0302	Vasculitis	292
THU0303–THU0328	Fibromyalgia and pain in rheumatic diseases	305
THU0329–THU0372	Epidemiology, health services and outcome research	314
THU0373–THU0385	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	331
THU0386–THU0410	SLE, Sjögren's and APS - treatment	336
THU0411–THU0436	Psoriatic arthritis	345
THU0437–THU0496	Osteoarthritis	358
THU0497–THU0538	Paediatric rheumatology	380
THU0539–THU0572	Other orphan diseases	395
THU0573–THU0590	Education	407
THU0591–THU0602	Rehabilitation	415

Friday, 12 June 2015**Guided Poster Tours**

F1: FRI0021–FRI0029	RA - predictors of complications and outcomes 2	426
F2: FRI0061–FRI0069	RA - comorbidities 1	441
F3: FRI0145–FRI0154	RA - safety and efficacy for treatment after TNF inhibitor	474
F4: FRI0190–FRI0197	Understanding spondyloarthritis	493
F5: FRI0244–FRI0255	Vasculitis	513
F6: FRI0283–FRI0292	Osteoporosis - new treatment options	527
F7: FRI0335–FRI0346	Epidemiology and health services research	546
F8: FRI0373–FRI0382	Lupus and APS - etiology, pathogenesis and new treatment approaches	562
F9: FRI0433–FRI0441	SSc pathogenesis and etiology	584
F10: FRI0494–FRI0503	PRoS: Clinical aspects of paediatric rheumatic diseases 1	611
F11: FRI0536–FRI0545	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	622
F12: FRI0560–FRI0568	New insights in diagnostic and prognostic markers in rheumatic diseases	630
F13: FRI0611-HPR–FRI0618-HPR	HPR: Multidisciplinary teams	1323
F14: PARE0012–PARE0021	PARE 2	1361

Posters

FRI0001–FRI0020	Adaptative immunity (T cells and B cells) in rheumatic diseases	420
FRI0021–FRI0060	Rheumatoid arthritis - prognosis, predictors and outcome	426
FRI0061–FRI0102	Rheumatoid arthritis - comorbidity and clinical aspects	441
FRI0103–FRI0144	Rheumatoid arthritis - anti-TNF therapy	456
FRI0145–FRI0189	Rheumatoid arthritis - other biologic treatment	474
FRI0190–FRI0197	Spondyloarthritis - etiology, pathogenesis and animal models	493
FRI0198–FRI0243	Spondyloarthritis - clinical aspects (other than treatment)	496
FRI0244–FRI0282	Vasculitis	513
FRI0283–FRI0308	Osteoporosis	527
FRI0309–FRI0334	Bone diseases other than osteoporosis, metabolic diseases and crystal diseases	536
FRI0335–FRI0372	Epidemiology, health services and outcome research	546
FRI0373–FRI0382	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	562
FRI0383–FRI0432	SLE, Sjögren's and APS - clinical aspects (other than treatment)	565
FRI0433–FRI0442	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models	584
FRI0443–FRI0493	Scleroderma, myositis and related syndromes - clinical aspects and treatment	587
FRI0494–FRI0535	Paediatric rheumatology	607
FRI0536–FRI0559	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	622
FRI0560–FRI0610	Diagnostics and imaging procedures	630

Saturday, 13 June 2015**Guided Poster Tours**

S1: SAT0001–SAT0008	Cytokines and inflammatory mediators	650
S2: SAT0033–SAT0041	Cartilage - bone - synovium: life in the joint	660
S3: SAT0052–SAT0061	RA - outcome	666
S4: SAT0096–SAT0105	RA - comorbidities 2: the heart at heart	684
S5: SAT0215–SAT0222	RA - small molecules 2	735
S6: SAT0270–SAT0279	SpA clinical abstracts	756
S7: SAT0305–SAT0314	Bone other than metabolic and crystals	768
S8: SAT0370–SAT0381	Sjögren's - pathogenesis and treatment targets	793
S9: SAT0382–SAT0391	SLE, Sjögren's, APS - clinical aspects	797
S10: SAT0432–SAT0443	Scleroderma - clinical aspects and treatment	816
S11: SAT0483–SAT0492	PRoS: Clinical aspects of paediatric rheumatic diseases 2	835
S12: SAT0523–SAT0534	Clinical features and treatment aspects of orphan diseases	849
S13: SAT0556–SAT0562	PsA - outcomes and treatment 2	861
S14: SAT0585–SAT0594	Imaging rheumatic diseases: what is new?	873
S15: SAT0638-HPR–SAT0645-HPR	HPR: Evidence based practice	1334

Posters

SAT0001–SAT0032	Cytokines and inflammatory mediators	650
SAT0033–SAT0051	Cartilage, synovium and osteoimmunology	660
SAT0052–SAT0095	Rheumatoid arthritis - prognosis, predictors and outcome	666
SAT0096–SAT0138	Rheumatoid arthritis - comorbidity and clinical aspects	684
SAT0139–SAT0179	Rheumatoid arthritis - anti-TNF therapy	701
SAT0180–SAT0214	Rheumatoid arthritis - other biologic treatment	720
SAT0215–SAT0232	Rheumatoid arthritis - non biologic treatment and small molecules	735
SAT0233–SAT0279	Spondyloarthritis - clinical aspects (other than treatment)	743
SAT0280–SAT0304	Osteoporosis	759
SAT0305–SAT0329	Bone diseases other than osteoporosis, metabolic diseases and crystal diseases	768
SAT0330–SAT0369	Epidemiology, health services and outcome research	778
SAT0370–SAT0381	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	793
SAT0382–SAT0431	SLE, Sjögren's and APS - clinical aspects (other than treatment)	797
SAT0432–SAT0482	Scleroderma, myositis and related syndromes - clinical aspects and treatment	816
SAT0483–SAT0522	Paediatric rheumatology	835
SAT0523–SAT0555	Other orphan diseases	849
SAT0556–SAT0584	Psoriatic arthritis	861
SAT0585–SAT0632	Diagnostics and imaging procedures	873

Abstracts Accepted for Publication

AB0001–AB0024	Genomics, genetics and epigenetics of rheumatic diseases	891
AB0025–AB0041	Adaptative immunity (T cells and B cells) in rheumatic diseases	899
AB0042–AB0054	Innate immunity in rheumatic diseases	904
AB0055–AB0082	Cytokines and inflammatory mediators	908
AB0083–AB0111	Cartilage, synovium and osteoimmunology	918
AB0112–AB0147	Rheumatoid arthritis - etiology, pathogenesis and animal models	928
AB0148–AB0158	Spondyloarthritis - etiology, pathogenesis and animal models	940
AB0159–AB0192	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	944
AB0193–AB0217	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models	955
AB0218–AB0225	Basic science in paediatric rheumatology	964
AB0226–AB0329	Rheumatoid arthritis - prognosis, predictors and outcome	967
AB0330–AB0409	Rheumatoid arthritis - comorbidity and clinical aspects	1003
AB0410–AB0435	Rheumatoid arthritis - anti-TNF therapy	1030
AB0436–AB0489	Rheumatoid arthritis - other biologic treatment	1040
AB0490–AB0515	Rheumatoid arthritis - non biologic treatment and small molecules	1062
AB0516–AB0536	SLE, Sjögren's and APS - treatment	1072
AB0537–AB0627	SLE, Sjögren's and APS - clinical aspects (other than treatment)	1079
AB0628–AB0669	Vasculitis	1109
AB0670–AB0734	Scleroderma, myositis and related syndromes - clinical aspects and treatment	1122
AB0735–AB0757	Spondyloarthritis - treatment	1144
AB0758–AB0793	Spondyloarthritis - clinical aspects (other than treatment)	1152
AB0794–AB0831	Psoriatic arthritis	1164
AB0832–AB0881	Osteoarthritis	1178
AB0882–AB0913	Osteoporosis	1195
AB0914–AB0930	Bone diseases other than osteoporosis, metabolic diseases and crystal diseases	1206
AB0931–AB0942	Infection-related rheumatic diseases	1211
AB0943–AB0952	Fibromyalgia and pain in rheumatic diseases	1214
AB0953–AB0961	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	1218
AB0962–AB1031	Paediatric rheumatology	1220
AB1032–AB1035	Other orphan diseases	1243
AB1036–AB1096	Diagnostics and imaging procedures	1244
AB1097–AB1194	Epidemiology, health services and outcome research	1267
AB1195–AB1201	Rehabilitation	1302
AB1202–AB1208	Education	1305

Health Professionals in Rheumatology Abstracts

Oral Presentations

Wednesday, 10 June 2015

OP0024-HPR	Ethnicity - a blind spot within rheumatology?	73
------------	---	----

Thursday, 11 June 2015

OP0094-HPR–OP0102-HPR	HPR Abstract session: Evidence based practice	104
OP0140-HPR–OP0141-HPR	Cardiovascular risk assessment - getting to grips with the challenges	121
OP0157-HPR	Innovations in healthcare - can you Google it?	128

Friday, 12 June 2015

OP0224-HPR–OP0231-HPR	HPR Abstract session: Getting to grips with evidence	156
OP0277-HPR	Social and work participation - research into practice	177
OP0286-HPR	Fit to fight rheumatic and musculoskeletal diseases - how much exercise is beneficial and safe?	180

Saturday, 13 June 2015

OP0298-HPR	Unlocking the mystery of health economics	185
OP0305-HPR	Quality indicators - a way to measure the quality of care	188

Poster Presentations

Thursday, 11 June 2015

Guided Poster Tours

T13: THU0603-HPR–THU0610-HPR	HPR: Getting to grips with the evidence	1310
------------------------------	---	------

Posters

THU0603-HPR–THU0639-HPR	Physiotherapy	1310
-------------------------	---------------------	------

Friday, 12 June 2015

Guided Poster Tours

F13: FRI0611-HPR–FRI0618-HPR	HPR: Multidisciplinary teams	1323
------------------------------	------------------------------------	------

Posters

FRI0611-HPR–FRI0616-HPR	Miscellaneous forms of clinical care	1323
FRI0617-HPR–FRI0635-HPR	Nursing	1325
FRI0636-HPR–FRI0639-HPR	Psychology/Social sciences	1331

Saturday, 13 June 2015

Guided Poster Tours

S15: SAT0638-HPR–SAT0645-HPR	HPR: Evidence based practice	1334
------------------------------	------------------------------------	------

Posters

SAT0633-HPR–SAT0637-HPR	Occupational therapy	1333
SAT0638-HPR–SAT0648-HPR	Miscellaneous forms of clinical care	1334

Abstracts Accepted for Publication

AB1209-HPR–AB1215-HPR	Nursing	1339
AB1216-HPR–AB1228-HPR	Psychology/Social sciences	1341
AB1229-HPR–AB1246-HPR	Physiotherapy	1345
AB1247-HPR–AB1249-HPR	Occupational therapy	1351
AB1250-HPR–AB1260-HPR	Miscellaneous forms of clinical care	1352

People with Arthritis and Rheumatism in Europe Abstracts

Oral Presentations

Wednesday, 10 June 2015

OP0014-PARE	Building sustainable relationships between patients and researchers	69
OP0025-PARE–OP0026-PARE	Measuring success - How to evaluate the impact of your campaign	74

Thursday, 11 June 2015

OP0111-PARE–OP0112-PARE	Championing work	110
OP0142-PARE–OP0143-PARE	Lost in the system - how to use innovative care to bring health services back to the patient	122
OP0158-PARE	Who cares? Primary care focus	128

Friday, 12 June 2015

OP0240-PARE–OP0247-PARE	PARE Abstract session	162
OP0287-PARE–OP0288-PARE	Youth in action	181

Saturday, 13 June 2015

OP0299-PARE–OP0300-PARE	Family business	186
OP0315-PARE	Taking control: success through empowerment and self-management	192

Poster Presentations

Thursday, 11 June to Saturday, 13 June 2015

Guided Poster Tours

Thursday, 11 June 2015

PARE 1 (PARE0001 to PARE0011)	1358
--	------

Friday, 12 June 2015

PARE 2 (PARE0012 to PARE0021)	1361
--	------

Posters

PARE0001	Psychosocial support	1358
PARE0002	Best practice campaigning	1358
PARE0003–PARE0005	Patient information and education	1358
PARE0006	Work and rehabilitation	1359
PARE0007–PARE0013	Patient information and education	1360
PARE0014	Best practice campaigning	1362
PARE0015	Arthritis research	1362
PARE0016	Best practice campaigning	1363
PARE0017	Work and rehabilitation	1363
PARE0018	Patient information and education	1364
PARE0019	Arthritis research	1364
PARE0020	Best practice campaigning	1364
PARE0021	Patient information and education	1365

Author Index	1367
---------------------------	------